89bio — Technical Presentation (September 2020)
22 slides from 89bio's technical presentation, Sep 14, 2020
Slide 1: BIO89-100 Phase 1b/2a Topline Results
Exhibit 99.2 Powerful Science Meaningful Medicines Changing Lives BIO89-100 Phase 1b/2a Topline Results Nasdaq: ETNB September 14, 2020Exhibit 99.2 Powerful Science Meaningful Medicines Changing Lives BIO89-100 Phase 1b/2a Topline Results Nasdaq: ETNB September 14, 2020
Slide 2: Disclaimer: Cautionary Note Regarding Forward-Looking Statements
Disclaimer CautionaryNoteRegardingForward-LookingStatements This presentation contains“forward-lookingstatements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements o
Slide 3: BIO89-100: Promising Benefit-Risk Profile with Convenient Dosing
BIO89-100: Promising Benefit-Risk Profile with Convenient Dosing EFFICACY RESULTS • Significant benefits across key liver parameters observed across all dose groups – Up to 60% reduction in liver fat versus baseline and up to 70% versus placebo – Up to 44% reduction in ALT (35 U/L decrease in high A
Slide 4: BIO89-100 Is An FGF21 Optimally Engineered for Efficacy and Long Dosing Interval
BIO89-100 Is An FGF21 Optimally Engineered To Balance Potential for Efficacy and Long Dosing Interval C-terminus C-terminus glycoPEG(20kD) FGF21 C-terminus C-terminus Strong and flexible linker FGF21 N-terminus N-terminus (glycoPEGylation technology) β-Klotho β-Klotho β-Klotho Position 182 Ns β-Klot
Slide 5: BIO89-100-002: Trial Design
BIO89-100-002: Trial Design KEY INCLUSION CRITERIA (n=9) 36mg (n=3) Placebo # • NASH* or phenotypic NASH (PNASH) (n=10) 27mg (n=3) • PDFF≥10% Placebo (n=11) 18mg *Subjects with biopsy-proven F1-3 (n=4) # Placebo Central obesity plus T2DM or evidence of liver injury 18mg (n=14) (n=4) Placebo KEY TRIA
Slide 6: Baseline Characteristics
Baseline Characteristics Pooled Parameter Placebo 3mg QW 9mg QW 18mg QW 27mg QW 18mg Q2W 36mg Q2W BIO89-100 Mean or % (n=19) (n=6) (n=12) (n=11) (n=10) (n=14) (n=9) (n=62) 52.6 51.7 56.1 49.5 51.5 52.0 51.2 52.5 Age (years) 36.8% 38.7% 16.7% 50% 27.3% 20% 28.6% 88.9% Male/Female 93.6 93.6 87.9 87.2
Slide 7: BIO89-100 Significantly Reduces Liver Fat Across All Dose Groups
BIO89-100 Significantly Reduces Liver Fat Across All Dose Groups Absolute Change in Liver Fat (%) from Baseline at Week 13 QW Q2W Placebo 3mg 9mg 18mg 27mg 18mg 36mg 5 • Up to 43% of subjects normalized their liver fat 1.4 (<5%) 0 • BIO89-100 significantly reduced liver volume up to 15% -5 • Changes
Slide 8: BIO89-100 Reduces Liver Fat in Significant Percentage of Subjects
BIO89-100 Reduces Liver Fat in Significant Percentage of Subjects Relative Reduction in Liver Fat from Baseline at Week 13 Proportion of Subjects with ≥30% QW Q2W Relative Reduction in Liver Fat Placebo 3mg 9mg 18mg 27mg 18mg 36mg 20% Placebo 0% 10% ** 3mg 60% 0% *** 9mg 82% ** 18mg 60% *** 27mg 86%
Slide 9: Majority of Subjects on BIO89-100 Achieved ≥50% Reduction in Liver Fat
Majority of Subjects on BIO89-100 Achieved ≥50% Reduction in Liver Fat Relative Reduction in Liver Fat versus Placebo at Week 13 Proportion of Subjects with ≥50% QW Q2W Relative Reduction in Liver Fat 3mg 9mg 18mg 27mg 18mg 36mg Placebo 0% -10% 3mg 20% ** 9mg 54% -30% ** 18mg 50% *** 27mg 71% *** **
Slide 10: Substantial Reduction in Liver Fat and Liver Volume (27mg QW)
BIO89-100 Showed Substantial Reduction in Liver Fat and Liver Volume After 12 Weeks of Treatment (Subject at 27mg QW) Liver fat (%) Parameter Baseline Week 13 % Change Liver fat 41.1% 5.1% -87.6% 1.4 -35.4% Liver volume (L) 2.2 8BIO89-100 Showed Substantial Reduction in Liver Fat and Liver Volume Af
Slide 11: Substantial Reduction in Liver Fat and Liver Volume (18mg Q2W)
BIO89-100 Showed Substantial Reduction in Liver Fat and Liver Volume After 12 Weeks of Treatment (Subject at 18mg Q2W) Liver fat (%) Parameter Baseline Week 13 % Change Liver fat 16.8% 3.5% -79.2% 0.9 -27.7% Liver volume (L) 1.2 9BIO89-100 Showed Substantial Reduction in Liver Fat and Liver Volume A
Slide 12: BIO89-100 Significantly Reduces ALT
BIO89-100 Significantly Reduces ALT Percent Change Over Time Percent Change from Baseline at Week 13 QW Q2W Baseline W7 W13 Placebo 3mg 9mg 18mg 27mg 18mg 36mg 20% -4% -10% 0% -17% * -19% -20% * * * -30% -27% -27% ** * * * *** *** -40% *** *** *** -40% Placebo 3 mg QW 9 mg QW *** 18 mg QW 27 mg QW 1
Slide 13: BIO89-100 Has Clinically Meaningful Impact on Subjects with High ALT
BIO89-100 has Clinically Meaningful Impact on Subjects with High ALT Absolute Change in ALT (U/L) Absolute Change in ALT at Week 13 (Baseline ALT > 45 U/L) (Baseline ALT > 45 U/L) Baseline W4 W7 W13 Pooled Placebo 10 BIO89-100 n=5 n=17 0 0 -10 -10 -10.5 -20 -17 units -20 -30 * -30 Placebo Pooled BIO
Slide 14: Significantly Improves Other Important Liver Biomarkers
BIO89-100 Significantly Improves Other Important Liver Biomarkers Despite Low Baseline Values AST PRO-C3 Percent Change from Baseline at Week 13 Percent Change from Baseline at Week 13 QW Q2W QW Q2W Placebo 3mg 9mg 18mg 27mg 18mg 36mg Placebo 3mg 9mg 18mg 27mg 18mg 36mg 0% 10% 3.3% 1.1% -4% -10% 0%
Slide 15: Significantly Reduces Triglycerides, Greater Benefit in High Triglycerides
BIO89-100 Significantly Reduces Triglycerides with Greater Benefit Observed in Subjects with High Triglycerides # Percentage Change from Baseline at Week 13 TG Normalization Rate at week 13 (All Subjects) (Subgroup with Baseline TG ≥200 mg/dL) Placebo Pooled BIO89-100 QW Q2W 60% Placebo 3mg 9mg 18mg
Slide 16: Significantly Improves Key Lipid Markers
BIO89-100 Significantly Improves Key Lipid Markers Percentage Change from Baseline At Week 13 Non-HDL LDL-c HDL-c QW Q2W QW Q2W 25% *** 20% 5% 5% * 20% 3% 18% 1% 1% 0% 0% 15% 11% -2% 10% 9% -5% -5% 10% -4% -5% -6% -6% -6% -8% 5% -10% -10% 3% 2% * 0% -15% -15% * -14% -14% * ** -16% -16% QW Q2W -20% -
Slide 17: Effect on Glycemic Control
BIO89-100 Effect on Glycemic Control Change From Baseline At Week 13 Placebo 3mg QW 9mg QW 18mg QW 27mg QW 18mg Q2W 36mg Q2W Adiponectin * * * *** * -4.3% 37.7% 25.5% 29.1% 60.9% 23.1% 24.1% Percentage Change & Insulin 10.0% -8.5% -9.4% -22.5% -6.9% -39.7% -34.5% Percentage Change HbA1c (%) <0.1 0.6
Slide 18: Safety Overview
Safety Overview Treatment Emergent Placebo 3mg QW 9mg QW 18mg QW 27mg QW 18mg Q2W 36mg Q2W Adverse Event (TEAE) (n=18) (n=7) (n=12) (n=11) (n=10) (n=14) (n=9) TEAE Leading to Death 0 0 0 0 0 0 0 TEAE Leading to a b 0 0 0 0 1 1 0 Discontinuation Serious Adverse Event 0 0 0 0 0 1 1 COVID 19 [Not Drug
Slide 19: Treatment Emergent Adverse Events in ≥10% of Pooled BIO89-100 Group
Treatment Emergent Adverse Event in ≥ 10% of Pooled BIO89-100 Group Pooled Preferred Term Placebo 3mg QW 9mg QW 18mg QW 27mg QW 18mg Q2W 36mg Q2W BIO89-100 n (%) (n=18) (n=7) (n=12) (n=11) (n=10) (n=14) (n=9) (n=63) Increased Appetite 0 15.9% 4 2 0 2 2 0 Diarrhea 22.2% 12.7% 1 2 0 2 1 2 Headache 5.6
Slide 20: BIO89-100 Has a Favorable Clinical Profile Relative to Leading NASH Classes
BIO89-100 Has a Favorable Clinical Profile Relative to Leading Classes in Development for NASH Relative Reduction in Liver Fat versus Placebo FGF21 FGF19 THRB FXR GLP-1 BIO89-100 Efruxifermin Pegbelfermin Aldafermin Resmetirom OCA Liraglutide 24 weeks 72 weeks 12 weeks 16 weeks 16 weeks 12 weeks 24
Slide 21: BIO89-100 – Demonstrating the Promise of FGF21 in NASH
BIO89-100 – Demonstrating the Promise of FGF21 in NASH SIGNIFICANT LIVER FAT REDUCTION IMPRESSIVE RESPONDER RATES AT HIGH THRESHOLD (≥50% FAT REDUCTION) LARGE, CLINICALLY MEANINGFUL CHANGES IN ALT ROBUST LIPID CHANGES – TRIGLYCERIDES, NON-HDL, LDL FAVORABLE SAFETY AND TOLERABILITY PROFILE WITH LIMIT
Slide 22: Powerful Science. Meaningful Medicines. Changing Lives.
Powerful Science. Meaningful Medicines. Changing Lives.Powerful Science. Meaningful Medicines. Changing Lives.